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Background: Aortic arch calciﬁcation is correlated with the extent of atherosclerosis and is a predictor of
future cardiovascular risk. The paraoxonase (PON) gene can reduce the risk of atherosclerosis develop-
ment. The purpose of this study was to determine the relationship between aortic arch calciﬁcation and
PON gene polymorphisms. We also evaluated the association between aortic arch calciﬁcation and the
presence of cardiovascular risk factors.
Methods: This study included 977 subjects (518 men and 459 women). Genotype polymorphisms include
PON1M55L, PON1Q192R, PON2A148G, and PON2S311C, as determined by melting point analysis using
LightCycler real-time polymerase chain reaction technology. Aortic arch calciﬁcations were assessed by
means of posteroanterior chest X-rays. Calciﬁcation severity was graded into four groups.
Results: There were no signiﬁcant differences in PON gene polymorphisms or allele frequencies between
the groups (p> 0.05). On simple regression analysis, aortic arch calciﬁcation was found to be associated
with age, hypertension, diabetes, and apolipoprotein A1 (ApoA1). On multiple regression analysis, aortic
arch calciﬁcation was found to be associated with age and ApoA1.
Conclusion: We did not ﬁnd an association between PON gene polymorphisms and aortic arch calciﬁ-
cation, but we did conﬁrm that aortic arch calciﬁcation is correlated with age and ApoA1.
Copyright  2010, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Atherosclerosis is a segmental disease within a given arterial bed
thatprogresses to involve the entire vasculature. It is characterizedby
the accumulationof lipids andﬁbrous elements in thegreater vessels,
such as the carotid artery and the aorta.1,2 Early atherosclerotic
lesions can usually be found in the aorta in the ﬁrst decade of life,
coronary arteries in the second decade, and cerebral arteries in the
third or fourth decades.2 The radiographic ﬁndings associated with
aortic calciﬁcation have been reported in large epidemiological
studies,3e6 which have shown an association between aortic calciﬁ-
cations and well-known cardiovascular risk factors.3e6 Additionally,
it has been reported that atherosclerosis of the ascending aorta is anerest.
ent of Neurology, Chonbuk
dong, Jeonju, Chonbuk 561-
s the ﬁrst author.
iwan Society of Geriatric Emergenindependent predictor of long-term neurological events and all-
cause mortality.7 Accordingly, atherosclerosis of the aorta may be
a marker of generalized atherosclerosis and is an important marker
because of its relationship with cerebrovascular ischemic disease
and with coronary atherosclerosis.
The paraoxonase (PON) gene family consists of three member
genes located adjacent to each otheron the long armof Chromosome
7 in humans. These genes play an important physiological role in
lipid metabolism through protection against the development of
atherosclerosis.8e12 PON1 inhibits oxidation of high-density lipo-
proteins (HDL) and low-density lipoproteins (LDL), increases cellular
cholesterol efﬂux from macrophages, ameliorates the effects of
oxidized LDL, and decreases lipid peroxides in atherosclerotic
lesions.10e12 The antioxidant and anti-inﬂammatory properties of
PON2 suggest that it plays an important physiological role in host
defense against atherosclerosis.8 The purpose of this study was to
determine if a correlation exists between the distribution of PON1
and PON2 polymorphisms and aortic calciﬁcation. We also
evaluated the association between aortic calciﬁcation and the
presence of cardiovascular risk factors.cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Sequences of primers, probes, and applied ﬂuorochromes used for PON1 and PON2
genotyping with melting point analysis on LightCycler.
Primer/probe Sequence
Primer
PON1-55F 5’-CCTGCAATAATATGAAACAACCTG-3’
PON1-55R 5’-CTAGAACACAGAAAAGTGAAAGAAAAC-3’
PON1-192F 5’-TATTGTTGCTGTGGGACCTGAG-3’
PON1-192R 5’-CCTTCTGCCACCACTCGAAC-3’
PON2-148F 5’-ATGAGCAGCTTCCCATCA-3’
PON2-148R 5’-CATGTACGGTGGTCTTATATTCATAC-3’
PON2-311F 5’-TTCAACAGCATGTCCCCTTAA-3’
PON2-311R 5’-CTTCCCATCATACACTGAGGCTA-3’
Probe
55-Sensor 5’-CTCTGAAGACATGGAGATACTGCC-FL-3’
55-Anchor 5’-LCRed640-ATGGACTGGCTTTCATTAGCTCTGTGAGGT-3’
192-Sensor 5’-CCCCTACTTACAATCCTGGGAGAT-FL-3’
192-Anchor 5’-LC705-ATTTGGGTTTAGCGTGGTCGTATGTTG-3’
148-Sensor 5’-GAACATTCTATCTGAGAAGCCTACAGTG-FL-3’
148-Anchor 5’-LC705-CTACAGTTTATGCCAACAATGGGTCTGTTC-3’
311-Sensor 5’-CATCCAGAACATTCTATGTGAGAA-FL-3’
311-Anchor 5’-LC640-CCTACAGTGACTACAGTTTATGCCAAC-3’
F¼ forward primer; R¼ reverse primer; LC Red 705¼ ﬂuorophore LightCycler Red
705; LC Red 640¼ ﬂuorophore LightCycler Red 640.
Paraoxonase and Aortic Calciﬁcation 1932. Materials and Methods
2.1. Subjects
This study included 353 subjects with aortic calciﬁcations (177
men and 176 women) and 624 subjects (341 men and 283 women)
without aortic calciﬁcations, all of whom were hospital patients or
outpatients presenting for health screening from August 2008 to
November 2009. Written informed consent was obtained from each
subject. The study protocol was approved by the Institutional Review
Board of National University Hospital. For the assessment of aortic
calciﬁcation, posterioreanterior chest X-ray was obtained during
deep inspiration in a standing position. For subjects who had
undergonemultiple radiographs, the chestX-rayclosest in time to the
review was chosen. The radiographs were read by radiologists
according to routine clinical practice. Films were not read for the
purpose of this study, and the radiologists were blinded to other
clinical informationabout the studysubjects. Calciﬁcationwasgraded
as follows: normal (no visible calciﬁcation), mild (small spots of
calciﬁcation or single thin calciﬁcation of the aortic knob), moderate
(one or more areas of thick calciﬁcation), and severe (circularTable 2
Clinical characteristics of entire study population and subgroups with aortic calciﬁcation
Characteristics Control group Calciﬁcation group
Normal (n¼ 619) Mild (n¼ 152) p
Age (yr) 62.6 12.1 69.39 9.1 <0.00
Sex, male, n (%) 399 (54.8) 83 (54.6) 0.94
Hypertension, n (%) 240 (38.7) 79 (51.9) 0.06
Diabetes mellitus, n (%) 101 (16.3) 25 (16.5) 0.87
Lipid proﬁles
Cholesterol (mg/dL) 190.9 39.8 185.9 39.7 0.87
Triglyceride (mg/dL) 140.1 101.4 130.8 87.3 0.49
HDL (mg/dL) 44.23 11.9 42.36 11.3 0.47
LDL (mg/dL) 116.5 33.7 113.8 32.4 0.35
LP(a) (mg/dL) 35.3 28.6 32.3 25.3 0.09
ApoA1 (g/L) 1.18 0.26 1.16 0.27 0.06
ApoB (g/L) 0.86 0.23 0.86 0.20 0.04
Homocysteine (umol/L) 10.7 4.79 11.0 6.0 0.07
Values are presented as mean standard deviation.
HDL¼ high-density lipoprotein; Apo¼ apolipoprotein; LP(a)¼ lipoprotein a.calciﬁcation of the aortic knob), in accordance with previous
studies.5,13 Risk factors evaluated for their association with aortic
calciﬁcation included age, sex, hypertension, diabetes mellitus, and
lipid proﬁle. We classiﬁed lipid proﬁles as high, normal, or low,
according to the previously deﬁned normal ranges (cholesterol,
0e200 mg/dL; triglyceride, 0e200 mg/dL; HDL cholesterol,
48.9e73.5 mg/dL; LDL cholesterol, 0e140 mg/dL; apolipoprotein A1
[ApoA1],1.08e2.24 g/L; ApoB, 0.60e1.17 g/L; lipoproteinA, 0e30mg/
dL; total homocysteine, 5e20 mmol/L).
2.2. Genotyping of DNA
Peripheral blood samples were collectedwith informed consent.
DNA was extracted using Nucleon DNA extraction kits (Tepnel Life
Sciences, Manchester, UK). DNA samples were quantiﬁed using
a GeneQuant II RNA/DNA calculator (Amersham-Pharmacia
Biotech, Uppsala, Sweden), and 5e10 ng of DNA from each subject
was ampliﬁed through a hot start polymerase chain reaction (PCR)
protocol. The sequences of primers and probes as well as the
applied ﬂuorophores and nucleotide sets applied for PON geno-
typing with melting point analysis are shown in Table 1. Both
primers and ﬂuorescently labeled probes were synthesized (TIB
MOLBIOL, Berlin, Germany). PCR and melting curve analysis were
performed in 20-mL volumes in glass capillaries (Hoffmann-La
Roche, Alameda, CA, USA).14 During PCR, the LightCycler
automate (software version 4.5, Roche Molecular. Biochemical,
Mannheim, Germany) continuously displays the current
ﬂuorescence and ﬂuorescence history of each capillary. Analysis
of PCR products on agarose gel and sequencing conﬁrmed the
presence of speciﬁc PCR products (data not shown). The observed
melting point was used as described in a previous study.15
2.3. Statistical analysis
Differences in demographic characteristics were compared by
univariate analysis using Student’s t test, and allele and genotype
frequencies were calculated by gene counting. The c2 test was used
both to estimate the HardyeWeinberg equilibrium and to compare
the genotype and allele frequencies between the aortic calciﬁcation
and normal subjects. One-way analysis of variance was used to
compare the mean levels of lipid parameters among the groups.
Logistic regression models were used to identify independent risk
factors for aortic arch calciﬁcation. The multivariate models
included covariates for age, sex, hypertension, diabetes mellitus,.
Moderate (n¼ 129) p Severe (n¼ 77) p
1 74.38 7.9 <0.001 75.64 6.2 <0.001
4 66 (51.2) 0.456 30 (39) 0.066
5 79 (61.2) 0.002 52 (67.5) 0.002
4 36 (27.9) 0.041 34 (44.1) <0.001
5 193.9 51.3 0.461 181.7 46.2 0.127
4 133.5 90.9 0.534 134.9 103.0 0.066
3 43.28 10.2 0.441 43.26 9.9 0.431
0 121.9 44.9 0.168 115.2 37.8 0.372
2 37.6 31 0.443 36.5 24 0.540
0 1.14 0.26 0.030 1.12 0.26 0.020
2 0.92 0.30 0.053 0.85 0.25 0.170
3 11.4 5.7 0.170 11.9 5.9 0.239
Table 3
Genotype and allele frequencies for PON gene cluster polymorphisms.
Genotype Control (n¼ 619) Group: aortic calciﬁcation (n¼ 358) Total (n¼ 977) p
Mild (n¼ 152) Moderate (n¼ 129) Severe (n¼ 77)
PON1M55L
LL, n (%) 546 (88.2) 137 (90.1) 114 (88.4) 70 (90.9) 867 (88.7) 0.837
LM, n (%) 73 (11.8) 15 (9.9) 15 (11.6) 7 (9.1) 110 (11.3)
MM, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
L, % 0.94 0.95 0.94 0.95 0.94 0.994
M, % 0.06 0.05 0.06 0.05 0.06
PON1Q192R
QQ, n (%) 255 (41.2) 63 (41.4) 49 (38.0) 30 (39.0) 397 (40.6) 0.899
QR, n (%) 364 (58.8) 89 (58.6) 80 (62.0) 47 (61.0) 580 (59.4)
RR, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Q, % 0.71 0.71 0.69 0.69 0.7 0.996
R, % 0.29 0.29 0.31 0.31 0.3
PON2A148G
AA, n (%) 380 (61.4) 94 (61.8) 79 (61.2) 53 (68.8) 606 (62.0) 0.802
AG, n (%) 215 (34.7) 55 (36.2) 45 (34.9) 22 (28.6) 337 (34.5)
GG, n (%) 24 (3.9) 3 (2.0) 5 (3.9) 2 (2.6) 34 (3.5)
A, % 0.79 0.8 0.79 0.83 0.79 0.945
G, % 0.21 0.2 0.21 0.17 0.21
PON2S311C
SS, n (%) 24 (3.9) 3 (2.0) 5 (3.9) 2 (2.6) 34 (3.5) 0.802
SC, n (%) 215 (34.7) 55 (36.2) 45 (34.9) 22 (28.6) 337 (34.5)
CC, n (%) 380 (61.4) 94 (61.8) 79 (61.2) 53 (68.8) 606 (62.0)
S, % 0.21 0.2 0.21 0.17 0.21 0.945
C, % 0.79 0.8 0.79 0.83 0.79
PON¼ paraoxonase.
J. Wu et al.194and lipid proﬁles. A value of p< 0.05 was considered statistically
signiﬁcant.
3. Results
The demography and characteristics of the entire study pop-
ulation, as well as subgroups with aortic calciﬁcation are presented
inTable 2. Therewasa signiﬁcantdifference in themeanagebetween
the control group and the calciﬁcation group (62.612.1 and
72.8 8.5, respectively; p< 0.001), and the mean ages of the mild,
moderate, and severe calciﬁcation groups are 63.39 9.1,
74.38 7.9, and 75.64 6.2, respectively. The severity of aortic
calciﬁcation increased with age (p< 0.001). The frequencies of
hypertension and diabetes were higher in the calciﬁcation group
(59.1% and 24.1%) than in the control group (39.6% and 16.3%)
(p< 0.001), and the frequency of hypertension increased with the
severity of aortic calciﬁcation.Table 4
Logistic regression analysis for the prediction of aortic calciﬁcation.
Variable Mild Moderate
Odds ratio 95% CI p Odds ratio 95% CI p
Age 3.18 2.14e4.71 <0.001 8.62 4.92e15.11 <
Sex 1.01 0.71e1.44 0.97 1.16 0.79e1.70
Hypertension 1.45 1.01e2.07 0.04 2.41 1.63e3.56 <
Diabetes 1.37 0.88e2.13 0.16 1.72 1.28e2.92
Triglyceride 1.08 0.61e1.92 0.80 2.87 1.28e6.42
Cholesterol 1.39 0.95e2.04 0.09 1.17 0.78e1.74
HDL cholesterol 0.70 0.44e1.13 0.14 0.75 0.47e1.19
LDL cholesterol 1.62 0.93e2.81 0.08 1.14 0.71e1.84
ApoA1 0.77 0.49e1.19 0.23 0.85 0.55e0.92
ApoB 1.86 0.83e4.29 0.13 1.23 0.67e2.32
LP(a) 1.20 0.79e1.82 0.41 1.18 0.78e1.79
Homocysteine 1.12 0.44e3.49 0.68 1.25 0.44e3.52
HDL¼ high-density lipoprotein; Apo¼ apolipoprotein; LP(a)¼ lipoprotein a; 95% CI¼ 95
Variables entered into a model; age >65 yr; triglyceride >200 mg/dL; cholesterol >200 m
dL; ApoA1 <1.08 g/L; ApoB >1.17 g/L; LP(a) >30 mg/dL; homocysteine >20 umol/L.The concentration of ApoA1 was signiﬁcantly different between
subjects with aortic calciﬁcation (1.14 0.26) and those without
aortic calciﬁcation (1.18 0.26) (p< 0.05). There was no signiﬁcant
difference between the groups in terms of other lipid parameters
(Table 2). The genotype and allele distribution of the four
polymorphisms are shown in Table 3. The prevalence of each
allele in each of the study groups was consistent with the
HardyeWeinberg equilibrium. There was no signiﬁcant
association among the four polymorphisms in the study groups.
We performed multivariate subgroup analysis for evaluating the
risk factors of aortic calciﬁcation. Age, hypertension, diabetes
mellitus, and ApoA1 were independent factors associated with
the presence of aortic calciﬁcation (Table 4). Diabetes and ApoA1
were risk factors of moderate to severe aortic calciﬁcation groups.
Multiple logistic regression analysis revealed that age and ApoA1
were independently related to the presence of aortic calciﬁcation
in the entire study population (Table 5).Severe Entire
Odds ratio 95% CI p Odds ratio 95% CI p
0.001 20.7 7.48e57.35 <0.001 6.2 4.47e8.61 <0.001
0.45 1.90 1.17e3.08 0.01 1.2 0.92e1.56 0.18
0.001 3.18 1.92e5.25 <0.001 1.89 1.45e2.44 <0.001
0.05 2.47 1.46e4.16 0.001 1.5 1.08e2.08 0.02
0.01 1.37 0.65e2.88 0.40 1.56 1.00e2.43 0.05
0.45 1.42 0.85e2.37 0.18 1.29 0.98e1.70 0.07
0.22 0.85 0.50e1.47 0.56 0.79 0.57e1.10 0.16
0.59 1.11 0.61e2.01 0.74 1.14 0.79e1.62 0.49
0.05 0.77 0.46e0.89 0.04 0.72 0.52e0.99 0.04
0.49 1.19 0.51e2.73 0.69 1.05 0.64e1.70 0.86
0.44 1.28 0.78e2.11 0.33 1.05 0.78e1.42 0.73
0.67 1.79 0.52e7.09 0.03 1.47 0.72e2.98 0.29
% conﬁdence interval.
g/dL; HDL cholesterol <48.9 mg/dL; low-density lipoprotein cholesterol >140 mg/
Table 5
Determinants of aortic calciﬁcation in multivariate analysis for the entire study
population.
Dependent variable Adjusted odds ratio 95% Conﬁdence interval p
Age 4.80 2.70e8.56 <0.001
ApoA1 0.72 0.51e0.89 0.04
Adjusted for age, hypertension, diabetes mellitus, cholesterol, triglyceride, ApoA1,
and high-density lipoprotein cholesterol.
Apo¼ apolipoprotein.
Paraoxonase and Aortic Calciﬁcation 1954. Discussion
Previous studies have shown that PONgene polymorphismsmay
play a signiﬁcant role in the prevention of oxidative damage, and
their protective role against the development of atherosclerosis,
coronary artery disease, and stroke has been investigated.15e20
A previous study demonstrated the validity of X-ray detection of
aortic calciﬁcations in the diagnosis of atherosclerosis, and
although the number of cases was small (n¼ 20), the X-ray ﬁndings
were compared with autopsy ﬁndings, which showed that radio-
graphs have high sensitivity.21 Calciﬁcation of the aortic arch is
a risk factor associated with coronary heart disease, stroke, and
peripheral vascular disease.4,5,22 In the present study, we evalu-
ated the association between aortic arch calciﬁcation and four PON
gene polymorphisms: PON1M55L, PON1Q192R, PON2A148G, and
PON2S311C. The allele frequencies and genotype distribution were
no different between the aortic calciﬁcation group and the normal
group. PON genotype and allele frequencies vary among ethnic
groups, and the PON enzyme activity level is more important than
the genotype when it comes to correlation with disease. Athero-
sclerosis is a complex process that might be inﬂuenced by many
environmental factors. It is difﬁcult to label one genetic poly-
morphism as instrumental in the mechanism of aortic calciﬁcation,
as genetic and environmental risk factors may interact in various
ways to either decrease or enhance susceptibility to atherosclerosis.
Further study will be needed establish the correlation between
PON activity level and aortic atherosclerosis in a large population.
Previous studies have demonstrated the association between
aortic calciﬁcation and several vascular risk factors, such as race,4
old age,6,23 hypertension,4,6,24 diabetes,6,25 smoking,4,26 C-reactive
protein,27,28 and serum total cholesterol.4,6,23,29 The present study
shows that aortic arch calciﬁcation correlates with old age, hyper-
tension, diabetes, and ApoA1. Aortic arch calciﬁcation was
frequently observed in older subjects, and a higher percentage of
subjects with hypertension and diabetes mellitus was found in the
aortic calciﬁcation subgroup than that in the noncalciﬁcation
group. These ﬁndings are consistent with previous studies. The old
age and frequency of hypertension are increased with severity of
aortic arch calciﬁcation, and frequency of diabetes is increased in
moderate to severe subgroups of aortic arch calciﬁcation. These
ﬁndings showed that the subjects with more risk factors are prone
to develop more severe aortic calciﬁcation.
Additionally, in this study, the concentration of ApoA1 showed
an inverse correlationwith the severity of aortic calciﬁcation. ApoA1
compromises 70e80% of the HDL protein and plays a critical role in
maintaining the integrity of HDL particles. Plasma levels of ApoA1
are inversely related to the risk of coronary heart disease, and some
subjects with ApoA1 deﬁciency develop early severe atheroscle-
rosis. Our ﬁndings imply that ApoA1 has antiatherogenic activity in
subjects with aortic calciﬁcation. Backward stepwise logistic
regression analysis was applied to identify factors that were inde-
pendently associated with the presence of aortic calciﬁcation. This
analysis revealed that age andApoA1were independently related to
the presence of aortic calciﬁcation. The aging process might inﬂu-
ence the pathogenesis of atherosclerosis in terms of physiologicalvascular changes and accumulating exposure to risk factors. Our
ﬁndings are in agreement with those of a previous study.30
Our study is limited in several ways. First, although we assessed
aortic calciﬁcation according to speciﬁc severity, not merely its
presence, we did not conﬁrm the presence of aortic calciﬁcation
using other methods, such as electron beam computed tomog-
raphy, computed tomography, and transesophageal echocardiog-
raphy. These methods might have been more speciﬁc in the
evaluation of aortic calciﬁcation. Second, we did not evaluate for
thoracic and lumbar lesions. Therefore, it is possible that the true
incidence of aortic calciﬁcation was underestimated.
In summary, we showed that PON polymorphisms and allele
frequencies are not correlated with aortic calciﬁcations on chest
X-ray. Further prospective and cross-sectional epidemiological
studies will be required to evaluate the exact role of PON in aortic
calciﬁcation. Such studies should include measurements of enzyme
activity in addition to determination of genetic polymorphisms.Acknowledgments
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